177Lu-DOTATATE and 131I-MIBG radioligand therapies achieve high disease control in advanced pheochromocytomas and paragangliomas.
Background
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors with significant clinical and biological heterogeneity. While surgery is curative for localized disease, many patients face unresectable, metastatic, or progressive disease, often accompanied by uncontrolled hormone secretion, necessitating alternative treatments. Standard pharmacological interventions often show poor response in metastatic cases. Advances in genetics have identified germline variants in 30-40% of cases, guiding the use of molecularly targeted imaging and therapies. This review highlights how functional imaging and radioligand therapies leverage tumor biology to improve diagnosis, prognosis, and treatment selection.
Study Design
This review details the application of functional imaging modalities and radioligand therapies for managing pheochromocytomas and paragangliomas (PPGLs). It describes diagnostic imaging using 68Ga or 64Cu-DOTA-SSA (somatostatin analogs), 18F-FDOPA, 18F-FDG, and 123I-MIBG, which exploit tumor characteristics like somatostatin receptor expression, catecholamine biosynthesis, and altered glucose metabolism. The paper then examines the therapeutic efficacy of radioligand therapies, specifically high-specific-activity 131I-MIBG and 177Lu-DOTATATE, as pivotal options for advanced, unresectable, or metastatic PPGLs.
Results
Functional imaging with 68Ga/64Cu-DOTA-SSA, 18F-FDOPA, 18F-FDG, and 123I-MIBG significantly improves diagnostic accuracy and aids in prognosis and therapy selection for PPGLs. Radioligand therapies have emerged as crucial for advanced disease. High-specific-activity 131I-MIBG has demonstrated durable disease control, symptomatic improvement, and a favorable safety profile in multicenter studies, leading to FDA approval for metastatic PPGL, although it is not currently commercially available. More recently, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE has shown remarkable efficacy. > 177Lu-DOTATATE achieved disease control rates of 80-100% in both prospective and retrospective trials, with outcomes further enhanced by standardized dosing strategies. Ongoing research is evaluating PRRT in genetically defined subgroups and exploring synergistic combinations, including radiosensitizing approaches, to further optimize patient outcomes.
Key Findings
- Functional imaging (
68Ga/64Cu-DOTA-SSA,18F-FDOPA,18F-FDG,123I-MIBG) improves PPGL diagnosis, prognosis, and therapy selection. - High-specific-activity 131I-MIBG demonstrated durable disease control and favorable safety, leading to FDA approval for metastatic PPGL.
- Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE achieved disease control rates of 80-100% in trials.
- Standardized dosing strategies enhance 177Lu-DOTATATE outcomes in advanced PPGLs.
Why It Matters
For patients with advanced or metastatic pheochromocytomas and paragangliomas (PPGLs), these radioligand therapies represent a significant advancement beyond conventional treatments, offering hope for durable disease control and improved quality of life. The high disease control rates observed with 177Lu-DOTATATE (80-100%) underscore its potential as a frontline or subsequent therapy for eligible patients. While 131I-MIBG is FDA-approved, its commercial unavailability highlights a critical gap. The focus on standardized dosing strategies for 177Lu-DOTATATE and ongoing studies into genetically defined subgroups suggest that treatment protocols will become increasingly personalized and effective, potentially integrating with other therapies to enhance synergistic effects and overcome resistance.
pheochromocytoma
paraganglioma
neuroendocrine-tumor
radioligand-therapy
177lu-dotatate
131i-mibg